IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Guardado en:

Detalles Bibliográficos
Autores principales:	Kristian Reich, Kilian Eyerich, Knut Schäkel, Peter Weisenseel, Andreas Pinter, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/673be33cf2a54e4aba93d38bcb985891
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:673be33cf2a54e4aba93d38bcb985891
record_format	dspace
spelling	oai:doaj.org-article:673be33cf2a54e4aba93d38bcb9858912021-11-09T05:30:05ZIL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)10.1136/bmjopen-2021-0498222044-6055https://doaj.org/article/673be33cf2a54e4aba93d38bcb9858912021-09-01T00:00:00Zhttps://bmjopen.bmj.com/content/11/9/e049822.fullhttps://doaj.org/toc/2044-6055Kristian ReichKilian EyerichKnut SchäkelPeter WeisenseelAndreas PinterKhusru AsadullahSven WegnerErnesto J Muñoz-EliasHolger BartzFriedmann J H TautBMJ Publishing GrouparticleMedicineRENBMJ Open, Vol 11, Iss 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Kristian Reich Kilian Eyerich Knut Schäkel Peter Weisenseel Andreas Pinter Khusru Asadullah Sven Wegner Ernesto J Muñoz-Elias Holger Bartz Friedmann J H Taut IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
format	article
author	Kristian Reich Kilian Eyerich Knut Schäkel Peter Weisenseel Andreas Pinter Khusru Asadullah Sven Wegner Ernesto J Muñoz-Elias Holger Bartz Friedmann J H Taut
author_facet	Kristian Reich Kilian Eyerich Knut Schäkel Peter Weisenseel Andreas Pinter Khusru Asadullah Sven Wegner Ernesto J Muñoz-Elias Holger Bartz Friedmann J H Taut
author_sort	Kristian Reich
title	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
title_short	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
title_full	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
title_fullStr	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
title_full_unstemmed	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
title_sort	il-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (guide)
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/673be33cf2a54e4aba93d38bcb985891
work_keys_str_mv	AT kristianreich il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT kilianeyerich il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT knutschakel il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT peterweisenseel il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT andreaspinter il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT khusruasadullah il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT svenwegner il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT ernestojmunozelias il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT holgerbartz il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide AT friedmannjhtaut il23blockadewithguselkumabpotentiallymodifiespsoriasispathogenesisrationaleandstudyprotocolofaphase3brandomiseddoubleblindmulticentrestudyinparticipantswithmoderatetosevereplaquetypepsoriasisguide
_version_	1718441302241050624

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Ejemplares similares